Castration-Resistant Prostate Cancer: Targeted Therapies and Individualized Treatment

Various molecular mechanisms have been implicated in the progression from hormone-sensitive to castration-resistant prostate cancer (CRPC). Novel targeted agents to treat CRPC have been developed that inhibit either androgen receptor (AR)-mediated signaling (AR antagonists and inhibitors of androgen...

Descripción completa

Detalles Bibliográficos
Autores principales: Aggarwal, Rahul, Ryan, Charles J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2011
Materias:
Academia-Pharma Intersect
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228103/
https://www.ncbi.nlm.nih.gov/pubmed/21339259
http://dx.doi.org/10.1634/theoncologist.2010-0216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228103/
https://www.ncbi.nlm.nih.gov/pubmed/21339259
http://dx.doi.org/10.1634/theoncologist.2010-0216

Ejemplares similares